Liquidia to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Liquidia Corporation (NASDAQ: LQDA) will participate in two upcoming investor conferences: the BTIG Biotechnology Conference 2022 on August 8 in New York, featuring CFO Michael Kaseta's live Fireside Chat at 2:00 p.m., and the Wedbush PacGrow 2022 Healthcare Conference on August 9, a virtual event. The biopharmaceutical firm specializes in pulmonary hypertension treatments, including its product YUTREPIA™ (treprostinil) inhalation powder. More details can be found at www.liquidia.com.

News Market Reaction – LQDA

+1.33%

+1.33% Session move

In the trading session that priced this news, LQDA gained 1.33%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MORRISVILLE, N.C., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will be participating at the following investor conferences next week:

BTIG Biotechnology Conference 2022
Date: Monday, August 8, 2022
Location: Hybrid Event at St. Regis Hotel, New York, New York
Chief Financial Officer Michael Kaseta will also participate in a live Fireside Chat at 2:00 p.m. To listen to the event, please contact your BTIG representative with interest.

Wedbush PacGrow 2022 Healthcare Conference
Date: Tuesday, August 9, 2022
Location: Virtual Event

About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and other applications of its PRINT® Technology. The company operates through its two wholly owned subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Liquidia Technologies has developed YUTREPIA™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH). Liquidia PAH provides the commercialization for pharmaceutical products to treat pulmonary disease, such as generic Treprostinil Injection. For more information, please visit www.liquidia.com.

Contact Information for Media & Investors
Jason Adair
Senior Vice President, Corporate Development and Strategy
919.328.4400
jason.adair@liquidia.com

 

FAQ

What are the dates for Liquidia Corporation's investor conferences in August 2022?

Liquidia Corporation will attend the BTIG Biotechnology Conference on August 8, 2022, and the Wedbush PacGrow Healthcare Conference on August 9, 2022.

Who is participating in the Fireside Chat at the BTIG Biotechnology Conference 2022?

CFO Michael Kaseta will participate in the Fireside Chat at the BTIG Biotechnology Conference 2022.

Where is the BTIG Biotechnology Conference 2022 being held?

The BTIG Biotechnology Conference 2022 will take place at the St. Regis Hotel in New York, New York.

Is the Wedbush PacGrow 2022 Healthcare Conference an in-person event?

No, the Wedbush PacGrow 2022 Healthcare Conference on August 9, 2022, is a virtual event.

What is YUTREPIA™ developed by Liquidia Corporation?

YUTREPIA™ (treprostinil) inhalation powder is a treatment for pulmonary arterial hypertension developed by Liquidia Corporation.